Meeting
2017 Gastrointestinal Cancers Symposium
Anti-KRAS siRNA nanoparticles for targeted colorectal cancer therapy.
Authors
Bradley Krasnick
Department of Surgery, Washington University School of Medicine, St. Louis, MO
Bradley Krasnick , Matthew S. Strand , Ye Bi , Peter S. Goedegebuure , Timothy Fleming , Samuel A. Wickline , Hua Pan , Ryan C Fields
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Translational Research
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract 636)
DOI
10.1200/JCO.2017.35.4_suppl.636
Abstract #
636
Poster Bd #
F10
Abstract Disclosures
Similar Posters
Poster
2016 Gastrointestinal Cancers Symposium
Predictive value of ERCC1 and KRAS in colorectal cancer patients with FOLFOX chemotherapy.
First Author: In Kyu Lee
Poster
2019 Gastrointestinal Cancers Symposium
Small bowel adenocarcinoma: A single center experience.
First Author: Lindsay Marie Hannan
Poster
2016 ASCO Annual Meeting
MAVERICC, a phase II study of mFOLFOX6-bevacizumab (BV) vs FOLFIRI-BV as first-line (1L) chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC): Outcomes by tumor location and KRAS status.
First Author: Heinz-Josef Lenz
Poster
2015 ASCO Annual Meeting
ERCC1 induction after oxaliplatin exposure may depend on KRAS mutational status in colorectal cancer patient: preliminary data from liquid biopsy.
First Author: Mariantonietta Di Salvatore